MAZE 10-Q: SEC filing

Maze Therapeutics

Filed with the SEC on · accession 0001193125-26-453619

MAZE filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +2.1% by the first close after the filing.

Summary of the filing

Maze Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results, license agreements, and a term loan facility.

Key details

FilerMaze Therapeutics, Inc.
LenderHercules Term Loan Facility
License partnerShionogi
License partnerNeurocrine
License partnerTrace

How MAZE stock reacted

Close before

$34.19

Nov 6, 2026

First close after

+2.11%

$34.91

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for MAZE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for MAZE?

Click here

Frequently asked questions

What did MAZE file with the SEC on Nov 9, 2026?

MAZE filed a 10-Q (SEC filing). Maze Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results, license agreements, and a term loan facility.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did MAZE stock react to this filing?

MAZE closed at $34.19 before the filing and $34.91 on Nov 9, 2026 (+2.11%).

Other MAZE SEC filings

Get alerts when MAZE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days